Researchers have received approval to start a Phase 2 clinical trial for a new treatment aimed at precancerous cervical lesions linked to high-risk human papillomavirus (hr-HPV). This investigational therapy, developed by Amplexd Therapeutics, uses a formulation of epigallocatechin gallate (EGCg) delivered as a vaginal suppository. The trial will take place at The Chinese University of Hong Kong and aims to evaluate the safety and effectiveness of this treatment in women diagnosed with low-grade cervical lesions and hr-HPV.

This research is significant because cervical cancer is a major health issue worldwide, with many women facing the stress of abnormal cervical screenings. Currently, about 5% of cervical screenings show abnormalities, which often lead to a watchful waiting approach rather than immediate treatment. This new therapy could provide a non-surgical option for women, potentially reducing the need for more invasive procedures and offering a more accessible treatment pathway.

The Phase 2 trial will assess how well the EGCg-based therapy can help reduce lesions and clear the virus, with results expected in early 2027. While previous studies have explored EGCg for treating HPV, this trial is crucial for determining its effectiveness in a larger group of women. As the therapy has not yet been approved by the U.S. Food and Drug Administration, its safety and efficacy are still under investigation.

For now, women concerned about cervical health should stay informed about their screening options and discuss any abnormalities with their healthcare providers. The development of new treatments like this one could eventually provide more choices for managing cervical health.

Source: globenewswire.com